Evidence map›Paper›PMID 40265021›Full record

ReviewFrontiers in oncology2025

The role and research progress of serine metabolism in tumor cells.

Hanning Lyu, Shuchang Bao, Lingyun Cai, Mengke Wang, Yuxin Liu, Yang Sun, Xiaoyang Hu

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Distinct molecular responses of human intestinal organoids to proton and photon radiation.American journal of physiology. Gastrointestinal and liver physiology · 2025
    Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hanning LyuSchool of Basic Medicine, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
Shuchang BaoSchool of Basic Medicine, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
Lingyun CaiSchool of Basic Medicine, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
Mengke WangSchool of Basic Medicine, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
Yuxin LiuSchool of Basic Medicine, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
Yang SunSchool of Basic Medicine, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
Xiaoyang HuSchool of Basic Medicine, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Serine is crucial for tumor initiation, progression, and adaptive immunity. Metabolic pathways for serine synthesis, acquisition, and utilization in tumors and tumor-associated cells are influenced by various physiological factors and the tumor microenvironment, leading to metabolic reprogramming and amplification. Excessive serine metabolism promotes abnormal macromolecule biosynthesis, mitochondrial dysfunction, and epigenetic modifications, driving malignant transformation, proliferation, metastasis, immune suppression, and drug resistance in tumor cells. Restricting dietary serine intake or reducing the expression of serine synthetic enzymes can effectively slow tumor growth and extend patient survival. Consequently, targeting serine metabolism has emerged as a novel and promising research focus in cancer research. This paper reviews serine metabolic pathways and their roles in tumor development. It summarizes the influencing factors of serine metabolism. The article explores the significance of serine synthesis and metabolizing enzymes, along with related biomarkers, in tumor diagnosis and treatment, providing new insights for developing targeted therapies that modulate serine metabolism in cancer.

Indexed as

cancerone-carbon metabolismserine catabolismserine metabolismthe immunosuppressive microenvironment

Identifiers

PMID40265021
PMCPMC12011608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.